Chancenoptimierung durch individualisierte ... - Tumorzentrum

More documents

Recommendations

Info

Clinical remission by Sorafenib followed by surgery and RNA-DC vaccination DTIC 10/09 – 12/09 DTIC + Sorafenib 12/09 – 06/10 Surg. brain, Fote + S 07/10 – 01/11 Surg. liver, 03/11 + start DC vaccination
Targeted Therapy: Sorafenib 12.01.2009 28.01.2009 29
Page 1 and 2: Melanom 2012: Chancenoptimierung du
Page 3 and 4: Systemtherapie des Melanoms bis 201
Page 7 and 8: Targeted Therapy - Inhibitoren Boss
Page 9 and 10: Kinaseinhibitor PLX4032 (Vemurafeni
Page 11 and 12: BRAF + Tumorlast +++ Dynamik +++ Ki
Page 13 and 14: Systemtherapie im Stadium IV Melano
Page 15 and 16: Systemtherapie im Stadium IV Melano
Page 17 and 18: Wirkmechanismus von Ipilimumab Die
Page 19 and 20: ASCO 2010 - Immuntherapie 19
Page 21 and 22: Case history details • MRT showin
Page 23 and 24: Case history details • Melanoma S
Page 25 and 26: DNCB / DTIC Immunchemotherapie CR 7
Page 27: Systemtherapie Stadium IV Melanom B
Page 31 and 32: MM Stadium IV: Therapieoptionen fü
Page 33 and 34: Therapieoptionen des Uvea Melanoms
Page 35: Melanom: Prognostische Faktoren 35
Page 38 and 39: Individualisierte Melanomtherapie G
Page 42 and 43: Melanom - Zukunft Protein und RNA A
Page 44 and 45: Dank - dem GMP Team B. Schuler-Thur
Page 46 and 47: Dank - allen Mitarbeitern der MM Am

Chancenoptimierung durch individualisierte ... - Tumorzentrum

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?